華潤雙鶴(600062.SH):作為境內代理人申報的八氟丙烷脂質微球注射液獲批上市
格隆匯11月24日丨華潤雙鶴(600062.SH)公佈,近日,由公司作為境內代理人申報的八氟丙烷脂質微球注射液(“該藥品”)獲得國家藥品監督管理局“國家藥監局”)的《藥品註冊證書》(證書編號:2022S01101),該藥品適用於:常規超聲心動圖顯影不夠清晰者,增強左室腔內膜邊界的識別。
該藥品由蘭索斯公司提供,根據雙方協議約定,華潤雙鶴為其在中華人民共和國(包括香港特別行政區和澳門特別行政區,不包括台灣地區)獨家代理。該藥品獲得《藥品註冊證書》,將進一步豐富公司產品線,有助於提升公司產品的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.